Cardiome Pharma (CRME) Tops Q1 EPS by 15c

Cardiome Pharma (NASDAQ: CRME) reported Q1 EPS of ($0.06), $0.15 better than the analyst estimate of ($0.21). Revenue for the quarter came in at $7.1 million versus the consensus estimate of $6.34 million.

For earnings history and earnings-related data on Cardiome Pharma (CRME) click here.

You May Also Be Interested In

• Is Treasury selloff a major issue for stock market bulls?
• Securitize Corp (SECZ) PT Lowered to $10 at Benchmark as Stock Plummets Post Q2 Earnings
• Benchmark Reiterates Buy Rating on Odysight.AI Inc. (ODYS)